As STING can sense the cytosolic DNA to activate the innate immune system by inducing type I IFNs and inflammatory cytokines, the STING modulators have been evaluated in clinical trials for treating advanced solid tumor, inflammatory diseases, and autoimmune diseases. Here, STING1 is linked to autoimmune disease.